{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:39Z","timestamp":1790743359368,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,2]]},"DOI":"10.1093\/jcag\/gwy055","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T11:09:18Z","timestamp":1537960158000},"page":"S17-S33","source":"Crossref","is-referenced-by-count":73,"title":["The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization"],"prefix":"10.1093","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-8426","authenticated-orcid":false,"given":"M Ellen","family":"Kuenzig","sequence":"first","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario IBD Centre, Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"Children\u2019s Hospital of Eastern Ontario IBD Centre, Department of Pediatrics and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lee","sequence":"additional","affiliation":[{"name":"McGill University Health Centre (MUHC) IBD Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E","family":"Targownik","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"Department of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"McGill University Health Centre (MUHC) IBD Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey C","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"Mount Sinai Hospital Centre for IBD, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Lee","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Cooke-Lauder","sequence":"additional","affiliation":[{"name":"Bataleur Enterprises Inc., Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K","family":"Murthy","sequence":"additional","affiliation":[{"name":"Canadian Gastro-Intestinal Epidemiology Consortium, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"issue":"9","key":"2019042409563605700_CIT0001","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"10006","key":"2019042409563605700_CIT0002","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): A cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"3","key":"2019042409563605700_CIT0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14712598.2017.1287170","article-title":"Top-down approach to biological therapy of Crohn\u2019s disease","volume":"17","author":"Hirschmann","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2019042409563605700_CIT0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1155\/2015\/627370","article-title":"Ulcerative colitis-associated hospitalization costs: A population-based study","volume":"29","author":"Coward","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"2019042409563605700_CIT0005","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/ibd.21878","article-title":"Direct medical cost of managing IBD patients: A Canadian population-based study","volume":"18","author":"Bernstein","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2019042409563605700_CIT0006","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/MIB.0000000000001147","article-title":"Cost of ulcerative colitis in Quebec, Canada: A retrospective cohort study","volume":"23","author":"Dan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"2019042409563605700_CIT0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1155\/2011\/157604","article-title":"Health care resource use and costs for Crohn\u2019s disease before and after infliximab therapy","volume":"25","author":"Loomes","year":"2011","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"2019042409563605700_CIT0008","doi-asserted-by":"crossref","first-page":"S-833","DOI":"10.1016\/S0016-5085(18)32835-X","article-title":"Direct costs of care among patients with inflammatory bowel disease before and after initiation of anti-TNF therapy","volume":"154","author":"Targownik","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"2019042409563605700_CIT0009","doi-asserted-by":"crossref","first-page":"542","DOI":"10.18553\/jmcp.2013.19.7.542","article-title":"Health plan utilization and costs of specialty drugs with 4 chronic conditions","volume":"19","author":"Gleason","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"2019042409563605700_CIT0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpeds.2012.03.045","article-title":"Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease","volume":"161","author":"Karve","year":"2012","journal-title":"J Pediatr"},{"issue":"1","key":"2019042409563605700_CIT0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ajg.2015.207","article-title":"Health insurance paid costs and drivers of costs for patients with Crohn\u2019s disease in the United States","volume":"111","author":"Park","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2019042409563605700_CIT0012","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3111\/13696998.2014.909436","article-title":"Inflammatory bowel disease: Healthcare costs for patients who are adherent or non-adherent with infliximab therapy","volume":"17","author":"Wan","year":"2014","journal-title":"J Med Econ"},{"issue":"11","key":"2019042409563605700_CIT0013","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjv117","article-title":"Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis","volume":"9","author":"Niewiadomski","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2019042409563605700_CIT0014","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.crohns.2013.11.017","article-title":"Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study","volume":"8","author":"Gibson","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2019042409563605700_CIT0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2036.2009.04228.x","article-title":"Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn\u2019s disease patients by Markov analysis","volume":"31","author":"Odes","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2019042409563605700_CIT0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MIB.0000000000000250","article-title":"Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom Study","volume":"21","author":"Burisch","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2019042409563605700_CIT0017","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MIB.0000000000000643","article-title":"Self-reported health care utilization of patients with inflammatory bowel disease correlates perfectly with medical records","volume":"22","author":"Severs","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2019042409563605700_CIT0018","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: Results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"issue":"1","key":"2019042409563605700_CIT0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gastrohep.2015.04.007","article-title":"Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study","volume":"39","author":"Aldeguer","year":"2016","journal-title":"Gastroenterol Hepatol"},{"issue":"11\u201312","key":"2019042409563605700_CIT0020","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2036.2010.04482.x","article-title":"Costs of care for Crohn\u2019s disease following the introduction of infliximab: A single-centre UK experience","volume":"32","author":"Sprakes","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2019042409563605700_CIT0021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/apt.12339","article-title":"A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn\u2019s disease","volume":"38","author":"Lindsay","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2019042409563605700_CIT0022","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1097\/MIB.0000000000000905","article-title":"Health services utilization, specialist care, and time to diagnosis with inflammatory bowel disease in immigrants to Ontario, Canada: A population-based cohort study","volume":"22","author":"Benchimol","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2019042409563605700_CIT0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.gastro.2011.03.050","article-title":"Outcomes of patients with Crohn\u2019s disease improved from 1988 to 2008 and were associated with increased specialist care","volume":"141","author":"Nguyen","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"2019042409563605700_CIT0024","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1097\/MIB.0000000000000965","article-title":"Predictors of emergency department use by persons with inflammatory bowel diseases: A population-based study","volume":"22","author":"Nugent","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2019042409563605700_CIT0025","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2011-301978","article-title":"Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients","volume":"61","author":"Murthy","year":"2012","journal-title":"Gut"},{"issue":"10","key":"2019042409563605700_CIT0026","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/ibd.21591","article-title":"Changes to surgical and hospitalization rates of pediatric inflammatory bowel disease in Ontario, Canada (1994\u20132007)","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2019042409563605700_CIT0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/MIB.0000000000000306","article-title":"Health care utilization in elderly onset inflammatory bowel disease: A population-based study","volume":"21","author":"Nguyen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2019042409563605700_CIT0028","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/j.gastro.2014.06.023","article-title":"Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease","volume":"147","author":"Benchimol","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"2019042409563605700_CIT0029","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2015.01.022","article-title":"Health care use by a population-based cohort of children with inflammatory bowel disease","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019042409563605700_CIT0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1472-6963-11-137","article-title":"Health service utilization in IBD: Comparison of self-report and administrative data","volume":"11","author":"Longobardi","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"2019042409563605700_CIT0031","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.cgh.2014.02.042","article-title":"Factors associated with readmissions and outcomes of patients hospitalized for inflammatory bowel disease","volume":"12","author":"Nguyen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2019042409563605700_CIT0032","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.cgh.2014.03.033","article-title":"Increased incidence of critical illness among patients with inflammatory bowel disease: A population-based study","volume":"12","author":"Marrie","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2019042409563605700_CIT0033","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"issue":"8","key":"2019042409563605700_CIT0034","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ajg.2012.127","article-title":"The epidemiology of colectomy in ulcerative colitis: Results from a population-based cohort","volume":"107","author":"Targownik","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2019042409563605700_CIT0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/MIB.0000000000000993","article-title":"Risk of surgery and mortality in elderly-onset inflammatory bowel disease: A population-based cohort study","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019042409563605700_CIT0036","article-title":"Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: Results from a provincial database","author":"Abou Khalil","journal-title":"J Gastrointest Surg 2018;22(1):124\u201332"},{"key":"2019042409563605700_CIT0037","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/DCR.0000000000000003","article-title":"Infliximab in ulcerative colitis: The impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada","volume":"57","author":"Moore","year":"2014","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"2019042409563605700_CIT0038","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/apt.12873","article-title":"The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: A time-trend study","volume":"40","author":"Reich","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"2019042409563605700_CIT0039","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/ajg.2012.333","article-title":"Decreasing colectomy rates for ulcerative colitis: A population-based time trend study","volume":"107","author":"Kaplan","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2019042409563605700_CIT0040","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/MIB.0000000000001211","article-title":"Clinical predictors of the risk of early colectomy in ulcerative colitis: A population-based study","volume":"23","author":"Al-Darmaki","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2019042409563605700_CIT0041","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MIB.0000000000001068","article-title":"Quality of care and outcomes among hospitalized inflammatory bowel disease patients","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2019042409563605700_CIT0042","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.gastro.2015.06.001","article-title":"Postoperative mortality among patients with inflammatory bowel diseases: A systematic review and meta-analysis of population-based studies","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"2019042409563605700_CIT0043","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn\u2019s disease: A systematic review and meta-analysis of population-based studies","volume":"109","author":"Frolkis","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019042409563605700_CIT0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jcag\/gwy009.031","article-title":"Disparities in the care of rural and urban Canadians with inflammatory bowel disease: A population-based study (abstract)","volume":"1","author":"Benchimol","year":"2018","journal-title":"J Can Assoc Gastroenterol"},{"issue":"12","key":"2019042409563605700_CIT0045","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/ajg.2017.394","article-title":"Surgical rates for Crohn\u2019s disease are decreasing: A population-based time trend analysis and validation study","volume":"112","author":"Ma","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2019042409563605700_CIT0046","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"2019042409563605700_CIT0047","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"issue":"11","key":"2019042409563605700_CIT0048","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3109\/00365529709002993","article-title":"Inflammatory bowel diseases: Health care and costs in Sweden in 1994","volume":"32","author":"Blomqvist","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"2019042409563605700_CIT0049","article-title":"News: The most expensive biologic treatments for chronic inflammatory disease dominate the Canadian market","author":"Patented Medicine Prices Review Board","year":"2016"},{"issue":"10","key":"2019042409563605700_CIT0050","doi-asserted-by":"crossref","first-page":"e0185500","DOI":"10.1371\/journal.pone.0185500","article-title":"A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease","volume":"12","author":"Pillai","year":"2017","journal-title":"PLoS One"},{"key":"2019042409563605700_CIT0051","volume-title":"Pharmastat Prescription Database","author":"IMS Brogan Inc","year":"2012"},{"issue":"11","key":"2019042409563605700_CIT0052","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1155\/2012\/984575","article-title":"Inflammatory bowel disease: A Canadian burden of illness review","volume":"26","author":"Rocchi","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"2019042409563605700_CIT0053","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3111\/13696998.2011.625746","article-title":"Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease","volume":"15","author":"Waters","year":"2012","journal-title":"J Med Econ"},{"issue":"4792898","key":"2019042409563605700_CIT0054","first-page":"7","article-title":"Steroid-free remission among canadian pediatric inflammatory bowel disease patients","volume":"2016","author":"Church","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"7","key":"2019042409563605700_CIT0055","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cgh.2017.01.035","article-title":"Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease: A population-based analysis","volume":"15","author":"Targownik","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019042409563605700_CIT0056","unstructured":"Lungu E , WarwickG. Potential Savings from Biosimilars in Canada. Patented Medicine Prices Review Board presentation in CADTH Symposium 2017. [Presentation]. 2017. <https:\/\/www.cadth.ca\/sites\/default\/files\/symp-2017\/presentations\/april24-2017\/Concurrent-Session-B4-Gary-Warwick.pdf> (Accessed March 16, 2018)."},{"key":"2019042409563605700_CIT0057","article-title":"New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016","volume-title":"Pharmafile","author":"Murray","year":"2016"},{"issue":"3","key":"2019042409563605700_CIT0058","doi-asserted-by":"crossref","first-page":"e0121759","DOI":"10.1371\/journal.pone.0121759","article-title":"The health care cost of dying: A population-based retrospective cohort study of the last year of life in Ontario, Canada","volume":"10","author":"Tanuseputro","year":"2015","journal-title":"PLoS One"},{"key":"2019042409563605700_CIT0059","volume-title":"Public Services for Ontarians: A Path to Sustainability and Excellence","author":"Drummond","year":"2012"},{"issue":"5","key":"2019042409563605700_CIT0060","doi-asserted-by":"crossref","first-page":"e0177211","DOI":"10.1371\/journal.pone.0177211","article-title":"High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study","volume":"12","author":"Murthy","year":"2017","journal-title":"PLoS One"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcag\/article-pdf\/2\/Supplement_1\/S17\/28515478\/gwy055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T19:32:33Z","timestamp":1662147153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/2\/Supplement_1\/S17\/5153302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":60,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2018,11,2]]},"published-print":{"date-parts":[[2019,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwy055","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,11,2]]}}}